Mandana Khalili, MD
1001 Potrero Ave, SFGH 5
San Francisco, CA 94110
Chief of Clinical Hepatology, San Francisco General Hospital
Assistant Director, Clinical and Translational Science Institute (CTSI)-Comprehensive Mentoring Program
Unit Director, CTSI- Mentor Consultation Services
My research focuses on natural history of chronic viral hepatitis (hepatitis B and hepatitis C), novel treatments for viral hepatitis, health services/health disparity in viral hepatitis, and evaluation of metabolic abnormalities and pathophysiology of diabetes within the context of hepatitis C and B. My group previously evaluated mechanisms of insulin resistance and secretion in a large cohort of hepatitis C infected patients, and is now examining how HCV affects insulin action among the high risk Latino population. We are studying insulin action over time, with and without HCV treatment, using direct measures of insulin secretion and insulin action. We are also studying the mechanisms of immune response to hepatitis C therapy through the Bay Area Hepatitis C Cooperative Study. Through community and participatory research, we are also evaluating hepatitis B management and liver cancer screening practices in hepatitis B-infected underserved populations including the impact of liver cancer screening on mortality. Our focus on health services research involves evaluation of the impact of educational interventions on patient and provider knowledge, attitudes, and barriers to hepatitis C and hepatitis B care as well as primary care-specialist care coordination and access to care for viral hepatitis. In addition, as one of the clinical research centers for the NIH-funded Hepatitis B Research Network, we are currently working on better understanding the natural history of chronic hepatitis B and the optimal long-term treatment for this disease.
Recent Articles (44)
The birth and potential death of IL28b genotyping for hepatitis C therapy. 2015; 12(2):55-57..
Diabetes and Prediabetes in Patients with Hepatitis B Residing in North America. Hepatology. 2015 Aug 8.
Is there a relationship between hepatitis B surface antibody status and diabetes? J Diabetes. 2015 Jul 23.
Reasons for HCV non-treatment in underserved African Americans: Implications for treatment with new therapeutics. Ann Hepatol. 2015 Mar-Apr; 14(2):234-42.
Assessment of HBV preventive services in a medically underserved asian and pacific islander population using provider and patient data. J Gen Intern Med. 2015 Jan; 30(1):68-74.
Liver inflammation is a risk factor for prediabetes in at-risk latinos with and without hepatitis C infection. Liver Int. 2015 Jan; 35(1):101-7.
Depression is not associated with peripheral insulin resistance in patients with chronic hepatitis C infection. J Viral Hepat. 2015 Mar; 22(3):272-80.
Characteristics of adults in the hepatitis B research network in north america reflect their country of origin and hepatitis B virus genotype. Clin Gastroenterol Hepatol. 2015 Jan; 13(1):183-92.
Education and counseling in the methadone treatment setting improves knowledge of viral hepatitis. J Subst Abuse Treat. 2014 Apr; 46(4):528-31.
Hepatitis B management in vulnerable populations: gaps in disease monitoring and opportunities for improved care. Dig Dis Sci. 2014 Jan; 59(1):46-56.
A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. Am J Public Health. 2013 Oct; 103(10):e81-8.
Hepatocellular screening in hepatitis-B infected Asian Americans. J Viral Hepat. 2013 Jul; 20(7):515-6.
Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. Liver Int. 2013 Aug; 33(7):999-1007.
Insulin sensitivity and variability in hepatitis C virus infection using direct measurement. Dig Dis Sci. 2013 Apr; 58(4):1141-8.
A mentor development program for clinical translational science faculty leads to sustained, improved confidence in mentoring skills. Clin Transl Sci. 2012 Aug; 5(4):362-7.
Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. Diabetes Care. 2012 May; 35(5):1090-4.
Hepatocellular carcinoma screening practices and impact on survival among hepatitis B-infected Asian Americans. J Viral Hepat. 2012 Aug; 19(8):594-600.
Assessment of factors associated with pre-diabetes in HCV infection including direct and dynamic measurements of insulin action. J Viral Hepat. 2012 Jul; 19(7):480-7.
Racial differences in hepatitis C treatment eligibility. Hepatology. 2011 Jul; 54(1):70-8.
Hepatitis B and hepatocellular carcinoma screening among Asian Americans: survey of safety net healthcare providers. Dig Dis Sci. 2011 May; 56(5):1516-23.
Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci. 2011 Jan; 56(1):213-9.
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology. 2010 Nov; 139(5):1602-11, 1611.e1.
Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. Hepatology. 2010 Jul; 52(1):38-46.
A glimpse of future hepatitis C virus treatment paradigms. Hepatology. 2010 Feb; 51(2):707-10.
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009 Aug 6; 361(6):580-93.
Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transpl. 2008 Oct; 14(10):1491-7.
Coinfection with Hepatitis Viruses and HIV Update. In: Peiperl L, Volberding PA, eds. HIV InSite Knowledge Base [textbook on-line]. 2006.
Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years. Clin Transplant. 2006 Jan-Feb; 20(1):1-9.
Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial. Dig Dis Sci. 2005 Jun; 50(6):1148-55.
Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant. 2005 Jan; 5(1):118-24.
Relative effects of insulin resistance and protease inhibitor treatment on lipid and lipoprotein metabolism in HIV-infected patients. HIV Clin Trials. 2004 Nov-Dec; 5(6):383-91.
Treatment of the hepatitis C virus in patients coinfected with HIV. Gastroenterol Clin North Am. 2004 Sep; 33(3):479-96, vii-viii.
Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. J Acquir Immune Defic Syndr. 2004 Apr 15; 35(5):464-72.
New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl. 2004 Mar; 10(3):349-55.
Methods for quantifying insulin resistance in human immunodeficiency virus-positive patients. Metabolism. 2003 Jul; 52(7):858-61.
Quantification of insulin-mediated glucose disposal in HIV-infected individuals: comparison of patients treated and untreated with protease inhibitors. J Acquir Immune Defic Syndr. 2003 May 1; 33(1):34-40.
Peiperl L, Volberding PA, eds. HIV InSite Knowledge Base [textbook on-line]. Coinfection with Hepatitis Viruses and HIV Update. 2003; Available from: HIV InSite.
Hepatitis C in the setting of HIV co-infection. Microbes Infect. 2002 Oct; 4(12):1247-51.
Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. Am J Gastroenterol. 2000 May; 95(5):1284-9.
Clinics in Liver Disease. Interferon Therapy of Hepatitis B. 1999; 3(2):363-87.
Ionescu-Shiley valve failure. II: Experience with 25 low-profile explants. Ann Thorac Surg. 1992 Jul; 54(1):117-22; discussion 122-3.
Ionescu-Shiley valve failure. I: Experience with 125 standard-profile explants. Ann Thorac Surg. 1992 Jul; 54(1):111-6.
The University of Ottawa Heart Institute Cardiac Transplant Program: the first 100 transplants. A pathologic study of the explanted hearts. Mod Pathol. 1992 Mar; 5(2):158-64.
Select data provided by UCSF Profiles, powered by CTSI at UCSF. Learn more about the data source.